Payment overview · 2025
General Payments
$282.13
17 reported records · 11 companies
Healthcare provider profile · identity verified
Michael Ourada, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAMBURG, IA · NPI 1427164789
Verified facts
What the public records show
CMS Open Payments records show Michael Ourada, MD received $282.13 in general payments during 2025 across 17 reported records.
Lilly USA, LLC accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.85 | 21.9% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $40.70 | 14.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.79 | 10.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.55 | 10.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.24 | 8.9% | 1 | 2025 |
| Hydrofera LLC | Unresolved — no canonical attribution shown | $21.43 | 7.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.43 | 6.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.27 | 5.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.01 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.22 | 5.0% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $11.64 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $282.13 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.85 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $28.55 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| HYDROFERA BLUE Normalized: hydrofera blue |
Device | Hydrofera LLC | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $11.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 281 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
281 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 587 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 88 |
| Gabapentin | Gabapentin | 483 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 418 | 75 |
| Furosemide | Furosemide | 388 | 76 |
| Meloxicam | Meloxicam | 316 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 286 | 72 |
| Potassium Chloride | Potassium Chloride | 286 | 41 |
| Eliquis | Apixaban | 281 | 33 |
| Metformin Hcl | Metformin Hcl | 279 | 54 |
| Lisinopril | Lisinopril | 260 | 56 |
| Omeprazole | Omeprazole | 255 | 48 |
| Tramadol Hcl | Tramadol Hcl | 247 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 30 |
| Montelukast Sodium | Montelukast Sodium | 203 | 41 |
| Trazodone Hcl | Trazodone Hcl | 199 | 32 |
| Losartan Potassium | Losartan Potassium | 197 | 44 |
| Mirtazapine | Mirtazapine | 178 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 174 | 41 |
| Simvastatin | Simvastatin | 173 | 33 |
| Carvedilol | Carvedilol | 168 | 41 |
| Donepezil Hcl | Donepezil Hcl | 156 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 31 |
| Celecoxib | Celecoxib | 142 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 135 | 21 |
| Alprazolam | Alprazolam | 125 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 24 |
| Bupropion Xl | Bupropion Hcl | 121 | 21 |
| Buspirone Hcl | Buspirone Hcl | 119 | 20 |
| Clonazepam | Clonazepam | 119 | 17 |
| Memantine Hcl | Memantine Hcl | 116 | 13 |
| Propranolol Hcl | Propranolol Hcl | 114 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 108 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 27 |
| Warfarin Sodium | Warfarin Sodium | 106 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 103 | 14 |
| Famotidine | Famotidine | 99 | 16 |
| Sertraline Hcl | Sertraline Hcl | 98 | 15 |
| Azithromycin | Azithromycin | 94 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 17 |
| Farxiga | Dapagliflozin Propanediol | 84 | 13 |
| Finasteride | Finasteride | 79 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 79 | 14 |
| Cephalexin | Cephalexin | 78 | 47 |
| Allopurinol | Allopurinol | 77 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 14 |
| Baclofen | Baclofen | 74 | suppressed |
| Glimepiride | Glimepiride | 74 | 20 |
| Linzess | Linaclotide | 73 | 13 |
| Trulicity | Dulaglutide | 71 | suppressed |
| Aripiprazole | Aripiprazole | 70 | 11 |
| Ozempic | Semaglutide | 68 | suppressed |
| Pregabalin | Pregabalin | 68 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 67 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 46 |
| Torsemide | Torsemide | 65 | 12 |
| Olanzapine | Olanzapine | 64 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | suppressed |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Cefdinir | Cefdinir | 61 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Prednisone | Prednisone | 59 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 12 |
| Sucralfate | Sucralfate | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Rexulti | Brexpiprazole | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Dutasteride | Dutasteride | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Levofloxacin | Levofloxacin | 36 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Nyamyc | Nystatin | 34 | 13 |
| Amoxicillin | Amoxicillin | 33 | 27 |
| Atenolol | Atenolol | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Oxycontin | Oxycodone Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Xtampza Er | Oxycodone Myristate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 12 |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 16 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ritonavir | Ritonavir | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $282.13 · 17 records | Lilly USA, LLC | CAPLYTA, ELIQUIS, EVENITY, HYDROFERA BLUE, Kerendia, MOUNJARO, NURTEC ODT, PROLIA, QULIPTA, WATCHMAN Access System, YUPELRI, ZEPBOUND, bio-ConneKt | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error